SG11202004019SA - Compositions and methods for the treatment of eye disorders - Google Patents
Compositions and methods for the treatment of eye disordersInfo
- Publication number
- SG11202004019SA SG11202004019SA SG11202004019SA SG11202004019SA SG11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- methods
- eye disorders
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741041231 | 2017-11-17 | ||
PCT/IB2018/057342 WO2019097318A1 (en) | 2017-11-17 | 2018-09-22 | Compositions and methods for the treatment of eye disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004019SA true SG11202004019SA (en) | 2020-05-28 |
Family
ID=66540065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004019SA SG11202004019SA (en) | 2017-11-17 | 2018-09-22 | Compositions and methods for the treatment of eye disorders |
Country Status (14)
Country | Link |
---|---|
US (1) | US10933052B2 (en) |
EP (1) | EP3651747A4 (en) |
JP (1) | JP7006990B2 (en) |
KR (1) | KR102349776B1 (en) |
CN (1) | CN111372576A (en) |
AU (1) | AU2018367909B2 (en) |
BR (1) | BR112020009361A2 (en) |
CA (1) | CA3081553C (en) |
IL (1) | IL274234B2 (en) |
MX (1) | MX2020004666A (en) |
RU (1) | RU2761436C1 (en) |
SG (1) | SG11202004019SA (en) |
WO (1) | WO2019097318A1 (en) |
ZA (1) | ZA202002066B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2918926T3 (en) * | 2016-10-04 | 2022-07-21 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
WO2019097381A1 (en) * | 2017-11-17 | 2019-05-23 | Cellix Bio Private Limited | Compounds, compositions and methods for treatment of eye disorders and skin diseases |
EP3749303A4 (en) * | 2018-02-05 | 2022-01-26 | Cellixbio Private Limited | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
WO2021113637A1 (en) * | 2019-12-04 | 2021-06-10 | Restore Vision, Llc. | Ophthalmic formulations for the treatment of presbyopia |
TWI819268B (en) | 2020-01-16 | 2023-10-21 | 詹姆斯 W 希爾 | Changing eye color by gene transduction |
IL298476A (en) * | 2020-05-26 | 2023-01-01 | Cellix Bio Private Ltd | Pharmaceutical formulations of pilocarpine r-(+)-lipoate |
WO2023052974A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Ocular compositions and methods for the treatment of ophthalmic diseases and disorders |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL50250A (en) | 1975-08-27 | 1980-01-31 | Hydrophilics Int Inc | Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups |
US4076942A (en) | 1975-10-01 | 1978-02-28 | Merck & Co., Inc. | Crystalline dipilocarpinium pamoate |
FR2424930A1 (en) | 1978-05-02 | 1979-11-30 | Inst Khim Drevesiny Akadem | NEW POLYMERS OF ALCOYL-1 (OXO-5 ALCOYL-4 TETRAHYDROFURYL-METHYL (3) -5) IMIDAZOLES AND CARBOXYALCOYL ETHERS OF POLYVINYL ALCOHOL, USED IN PARTICULAR AS M-CHOLINOMEDETIC AND PREPARATION AGENTS |
NL8800099A (en) | 1987-01-31 | 1988-08-16 | Sandoz Ag | PILOCARPINE DERIVATIVES AND METHODS FOR PREPARING AND USING THESE DERIVATIVES. |
US4977176A (en) | 1987-01-31 | 1990-12-11 | Sandoz Ltd. | Pilocarpine compounds which are used as pharmaceutical agents |
US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
JP2771257B2 (en) | 1989-06-22 | 1998-07-02 | 岩城製薬株式会社 | Preparation of imidazole derivatives |
US5322942A (en) | 1991-06-03 | 1994-06-21 | Regents Of The University Of California | Synthesis of optically active lactones from L-aspartic acid and intermediates thereof |
DE4222459C2 (en) | 1992-07-08 | 1995-09-14 | Sigma Tau Ind Farmaceuti | 3,9-disubstituted-spiro [5.5] undecane, a process for their preparation and pharmaceutical compositions containing them |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
IS2334B (en) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
DE4334135A1 (en) | 1993-10-07 | 1995-04-13 | Merck Patent Gmbh | Process for the preparation of pilocarpine derivatives |
IL113459A (en) | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
CA2230894A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US6239180B1 (en) | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
US5994378A (en) | 1996-01-22 | 1999-11-30 | Fujisawa Pharmaceutical Co., Ltd. | Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them |
US6267983B1 (en) | 1997-10-28 | 2001-07-31 | Bando Chemical Industries, Ltd. | Dermatological patch and process for producing thereof |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
DE19827732A1 (en) | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermal patch useful for hormone replacement therapy used for treatment of menopausal symptoms |
US6222039B1 (en) | 1998-07-13 | 2001-04-24 | Hoffman-La Roche Inc. | Process for the preparation of chiral lactones |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6312716B1 (en) | 1999-05-10 | 2001-11-06 | Peierce Management Llc | Patch and method for transdermal delivery of bupropion base |
TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
CA2445625C (en) | 2001-06-05 | 2010-07-27 | Lilly Icos Llc | Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives |
FR2832637B1 (en) * | 2001-06-07 | 2004-07-30 | Lefaix Marie Therese Droy | USE OF AN ANTIOXIDANT FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF EYE SURFACE CONDITIONS |
CN101723941A (en) | 2002-08-09 | 2010-06-09 | 阿斯利康(瑞典)有限公司 | “1,2,4” oxadiazole as a metabotropic glutamate receptor-5 modulator |
CA2499601A1 (en) | 2002-09-19 | 2004-04-01 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
DE10358539A1 (en) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | carboxamide |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
CA2559408C (en) | 2004-03-15 | 2014-05-13 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
EP2046773A1 (en) * | 2006-06-16 | 2009-04-15 | Indigene Pharmaceuticals Inc. | Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications |
PL2044056T3 (en) | 2006-07-14 | 2013-01-31 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
GB0724558D0 (en) * | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
MX2010007604A (en) | 2008-01-11 | 2010-08-02 | Novartis Ag | Pyrimidines as kinase inhibitors. |
CA2716514A1 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
CA2731196A1 (en) | 2008-07-18 | 2010-01-21 | Takeda Pharmaceuticals Company Limited | Benzazepine derivatives and their use as hstamine h3 antagonists |
US20110091459A1 (en) | 2008-12-11 | 2011-04-21 | Auspex Pharmaceuticals, Inc. | Imidazole modulators of muscarinic acetylcholine receptor m3 |
WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
PL2470191T3 (en) * | 2009-08-24 | 2014-09-30 | Stealth Peptides Int Inc | Methods and compositions for preventing or treating ophthalmic conditions |
WO2011113060A2 (en) | 2010-03-12 | 2011-09-15 | Trana Discovery, Inc. | Antiviral compounds and methods of use thereof |
GB201007187D0 (en) | 2010-04-29 | 2010-06-09 | Iti Scotland Ltd | Ubiquitination modulators |
EP2575764B1 (en) | 2010-06-03 | 2017-04-19 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
HUE042165T2 (en) | 2010-06-23 | 2019-06-28 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
CN102432598A (en) | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | Tricyclic compound, preparation method thereof and pharmaceutical application thereof |
WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
JP2014504362A (en) | 2010-11-30 | 2014-02-20 | ジェネンテック, インコーポレイテッド | Assays and biomarkers for LRRK2 |
WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
ES2571741T3 (en) | 2011-03-31 | 2016-05-26 | Bayer Ip Gmbh | Substituted benzimidazoles as Mps-1 kinase inhibitors |
WO2012136531A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridines and intermediates thereof |
JP2012230356A (en) | 2011-04-15 | 2012-11-22 | Sumitomo Chemical Co Ltd | Compound, resist composition and method for producing resist pattern |
GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
US20140228384A1 (en) | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
BR112014018341A8 (en) | 2012-01-28 | 2017-07-11 | Merck Patent Gmbh | AZA-HETEROCYCLIC COMPOUNDS |
WO2013144191A1 (en) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases |
KR101586789B1 (en) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same |
WO2014124141A1 (en) * | 2013-02-07 | 2014-08-14 | Mylari Banavara L | Metformin derivatives for treating diabetes |
WO2015018754A1 (en) | 2013-08-08 | 2015-02-12 | Boehringer Ingelheim International Gmbh | Novel pyrazine amide compounds |
WO2015082378A1 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2015082376A2 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
US20160317606A1 (en) * | 2014-01-06 | 2016-11-03 | Stealth Bio Therapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
CN106795118B (en) | 2014-07-01 | 2019-10-08 | 武田药品工业株式会社 | Heterocyclic compound and their purposes as relevant orphan receptor (ROR) the GAMMA-T inhibitor of retinoids |
CN104387364B (en) | 2014-12-15 | 2016-11-16 | 南京工业大学 | L-Orn thioctic acid complex salt and its preparation method and application |
ES2918926T3 (en) | 2016-10-04 | 2022-07-21 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
-
2018
- 2018-09-22 AU AU2018367909A patent/AU2018367909B2/en active Active
- 2018-09-22 CN CN201880071277.XA patent/CN111372576A/en active Pending
- 2018-09-22 KR KR1020207017159A patent/KR102349776B1/en active IP Right Grant
- 2018-09-22 JP JP2020526481A patent/JP7006990B2/en active Active
- 2018-09-22 WO PCT/IB2018/057342 patent/WO2019097318A1/en unknown
- 2018-09-22 EP EP18879678.3A patent/EP3651747A4/en not_active Withdrawn
- 2018-09-22 BR BR112020009361-0A patent/BR112020009361A2/en active Search and Examination
- 2018-09-22 SG SG11202004019SA patent/SG11202004019SA/en unknown
- 2018-09-22 RU RU2020119218A patent/RU2761436C1/en active
- 2018-09-22 MX MX2020004666A patent/MX2020004666A/en unknown
- 2018-09-22 CA CA3081553A patent/CA3081553C/en active Active
-
2020
- 2020-02-13 US US16/790,492 patent/US10933052B2/en active Active
- 2020-04-26 IL IL274234A patent/IL274234B2/en unknown
- 2020-05-04 ZA ZA2020/02066A patent/ZA202002066B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10933052B2 (en) | 2021-03-02 |
US20200179343A1 (en) | 2020-06-11 |
IL274234B (en) | 2022-10-01 |
MX2020004666A (en) | 2022-01-26 |
RU2761436C1 (en) | 2021-12-08 |
KR102349776B1 (en) | 2022-01-10 |
AU2018367909B2 (en) | 2022-03-10 |
BR112020009361A2 (en) | 2020-10-13 |
IL274234A (en) | 2020-06-30 |
CA3081553C (en) | 2022-11-15 |
CA3081553A1 (en) | 2019-05-23 |
EP3651747A1 (en) | 2020-05-20 |
IL274234B2 (en) | 2023-02-01 |
NZ763688A (en) | 2021-10-29 |
JP7006990B2 (en) | 2022-02-10 |
CN111372576A (en) | 2020-07-03 |
WO2019097318A1 (en) | 2019-05-23 |
KR20200089292A (en) | 2020-07-24 |
AU2018367909A1 (en) | 2020-05-07 |
ZA202002066B (en) | 2021-07-28 |
JP2021503449A (en) | 2021-02-12 |
EP3651747A4 (en) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3675882A4 (en) | Methods and compositions for treatment of microbiome-associated disorders | |
IL268406A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
IL298690B1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EP3347469A4 (en) | Methods and compositions for the treatment of glaucoma | |
ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
HK1256721A1 (en) | Compounds and compositions for the treatment of ocular disorders | |
GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
IL259861A (en) | Methods and compositions for the treatment of seizure-related disorders | |
IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
IL275182A (en) | Compositions and methods for the treatment of metabolic conditions | |
SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
IL267229A (en) | Methods of treating ocular disorders | |
EP3429584A4 (en) | Compositions and methods for the treatment of presbyopia | |
IL275985A (en) | Compositions and methods for treating retinal disorders | |
IL272121A (en) | Composition and methods for the treatment of myopia | |
IL269400A (en) | Drugs and compositions for the treatment of ocular disorders | |
SG11201809811VA (en) | Compositions and methods for treatment of inflammation or infection of the eye | |
SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
EP3697354A4 (en) | Compositions and methods for treating eye disorders | |
IL282455A (en) | Methods and compositions for the treatment of secretory disorders | |
HK1258884A1 (en) | Compositions and methods for the treatment of sinus disease and disorders | |
EP3658217A4 (en) | Treatment of eye disorders | |
ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
ZA202004110B (en) | Compositions and methods for the treatment of metabolic conditions | |
EP3658218A4 (en) | Treatment of eye disorders |